Werewolf Therapeutics, Inc. (HOWL)

NASDAQ: HOWL · IEX Real-Time Price · USD
6.48
+0.13 (2.05%)
At close: Mar 28, 2024, 4:00 PM
6.51
+0.03 (0.46%)
After-hours: Mar 28, 2024, 4:47 PM EDT
2.05%
Market Cap 276.94M
Revenue (ttm) 19.94M
Net Income (ttm) -37.37M
Shares Out 42.74M
EPS (ttm) -1.05
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 152,663
Open 6.43
Previous Close 6.35
Day's Range 6.24 - 6.66
52-Week Range 1.57 - 8.19
Beta 0.73
Analysts Strong Buy
Price Target 10.58 (+63.27%)
Earnings Date Mar 7, 2024

About HOWL

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Apr 30, 2021
Employees 47
Stock Exchange NASDAQ
Ticker Symbol HOWL
Full Company Profile

Financial Performance

In 2023, HOWL's revenue was $19.94 million, an increase of 21.60% compared to the previous year's $16.40 million. Losses were -$37.37 million, -30.56% less than in 2022.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for HOWL stock is "Strong Buy." The 12-month stock price forecast is $10.58, which is an increase of 63.27% from the latest price.

Price Target
$10.58
(63.27% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

–  Additional monotherapy dose-escalation data from ongoing Phase 1/1b clinical trial of WTX-124 expected to be presented in the first half of 2024  –

21 days ago - GlobeNewsWire

Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma Conference

WATERTOWN, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of con...

22 days ago - GlobeNewsWire

Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024

WATERTOWN, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of con...

23 days ago - GlobeNewsWire

Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook

-  Prioritizing development of wholly owned clinical assets, WTX-124 and WTX-330; key updates from both INDUKINE TM programs anticipated in 2024 -

2 months ago - GlobeNewsWire

Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors

WATERTOWN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of nove...

3 months ago - GlobeNewsWire

Werewolf Therapeutics to Present at the Evercore ISI HealthCONx Conference

WATERTOWN, Mass., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of cond...

4 months ago - GlobeNewsWire

Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

–  Preliminary data from the WTX-124 monotherapy dose-escalation arm of the ongoing Phase 1/1b clinical trial provide compelling early evidence of dose-dependent anti-tumor and biomarker activity –

4 months ago - GlobeNewsWire

Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

WATERTOWN, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) --  Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of con...

5 months ago - GlobeNewsWire

Werewolf Therapeutics to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

WATERTOWN, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of cond...

5 months ago - GlobeNewsWire

Werewolf Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

WATERTOWN, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of con...

6 months ago - GlobeNewsWire

Werewolf Therapeutics to Host KOL Event Highlighting IL-2 Landscape and Opportunity for WTX-124

Virtual event to be held on Monday, September 18, 2023, at 10:00 am ET Virtual event to be held on Monday, September 18, 2023, at 10:00 am ET

7 months ago - GlobeNewsWire

Werewolf Therapeutics to Participate in Upcoming Investor Conferences

WATERTOWN, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of con...

7 months ago - GlobeNewsWire

Werewolf Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

- Phase 1/1b clinical trial for IL-2 INDUKINE™ WTX-124 progressing in patients with advanced or metastatic solid tumors; initial first-in-human clinical data from monotherapy dose-escalation arm expec...

8 months ago - GlobeNewsWire

Werewolf Therapeutics to Present at the Jefferies Healthcare Conference

WATERTOWN, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of cond...

10 months ago - GlobeNewsWire

Werewolf Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

- Progressing Phase 1/1b clinical trial for IL-2 INDUKINE WTX-124 in advanced or metastatic solid tumors; initial first-in-human clinical data from monotherapy dose-escalation arm expected in 4Q 2023 ...

11 months ago - GlobeNewsWire

Werewolf Therapeutics to Participate in May Investor Conferences

WATERTOWN, Mass., May 01, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of condi...

11 months ago - GlobeNewsWire

Werewolf Therapeutics Publishes Preclinical Data on mWTX-330, an IL-12 INDUKINE™ Molecule, in Cancer Immunology Research

WATERTOWN, Mass., April 19, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of con...

1 year ago - GlobeNewsWire

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

– Initial first-in-human clinical data for IL-2 INDUKINE WTX-124 monotherapy expected in 4Q 2023 from Phase 1/1b clinical trial in advanced or metastatic solid tumors –

1 year ago - GlobeNewsWire

UPDATE -- Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2023

WATERTOWN, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of con...

1 year ago - GlobeNewsWire

Werewolf Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2023

CAMBRIDGE, Mass., March 15, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of con...

1 year ago - GlobeNewsWire

Werewolf Therapeutics Announces Initiation of Patient Dosing in Phase 1 Study of WTX-330

WTX-330 is designed as systemically delivered, conditionally activated IL-12 therapy

1 year ago - GlobeNewsWire

Werewolf Therapeutics to Present at the SVB Securities Global Biopharma Conference

WATERTOWN, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL) today announced that Randi Isaacs, M.D., Chief Medical Officer of Werewolf,...

1 year ago - GlobeNewsWire

Werewolf Therapeutics Presents Preclinical Data on mWTX-330, a Surrogate IL-12 INDUKINE™ Molecule, at the Society for Immunotherapy of Cancer Annual Meeting

- mWTX-330 is designed as a systemically delivered, conditionally activated IL-12 therapy and is a member of a novel class of INDUKINE™ therapeutics -

1 year ago - GlobeNewsWire

Werewolf Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

WATERTOWN, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of cond...

1 year ago - GlobeNewsWire

Werewolf Therapeutics to Present Preclinical Data at Society for Immunotherapy of Cancer Annual Meeting and Participate in Upcoming Investor Conferences

WATERTOWN, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of cond...

1 year ago - GlobeNewsWire